title: Predictive value of early virologic response in HIV/hepatitis C virus-coinfected patients treated with an interferon-based regimen plus ribavirin.
abstract: BACKGROUND
  As a result of adverse events, a moderate rate of virologic response, and high costs associated with hepatitis C virus (HCV) therapy, finding early markers of sustained treatment response is a clinical priority. In the HCV-monoinfected population, a reduction >or=2 log in plasma HCV RNA at week 12 of therapy (early virologic response [EVR]) predicts a sustained virologic response (SVR). Few data are available in HIV/HCV-coinfected patients, however.
  
  
  METHODS
  A subanalysis of data from HIV/HCV-coinfected patients treated with pegylated interferon-alpha-2b (PEG, 100-150 mug/wk) or interferon-alpha-2b (IFN, 3 MIU 3 times per week) plus ribavirin (RBV, 800-1200 mg/d) was conducted in a randomized single-center clinical trial. The duration of treatment was 48 weeks (only 24 weeks for HCV genotype 2 or 3 with a baseline HCV RNA level <800,000 IU/mL).
  
  
  RESULTS
  Ninety-five patients were randomized (43 assigned to IFN + RBV and 52 assigned to PEG + RBV). Eighty patients completed at least 12 weeks on therapy and were included in the EVR analysis. Thirty-five (43%) of them attained an SVR (56% and 30% of patients treated with PEG and IFN, respectively; P = 0.026). An EVR occurred in 55 (69%; 80% of PEG + RBV group and 56% of IFN + RBV group). Overall, 35 of 55 patients with an EVR were sustained responders, yielding a positive predictive value of 64% (70% in PEG + RBV arm and 55% in IFN + RBV arm). None of the patients who demonstrated an HCV RNA decline of <2 logs at week 12 reached an SVR (negative predictive value of 100%).
  
  
  CONCLUSIONS
  Our results confirm the utility of an EVR to predict the chance of the lack of an SVR in HIV/HCV-coinfected patients, particularly those treated with PEG.
authors.affiliation: Infectious Diseases Service, Hospital Clínic Universitari de Barcelona, Barcelona, Spain. mlaguno@clinic.ub.es
authors.forename: Montserrat
authors.initials: M
authors.lastname: Laguno
authors.forename: María
authors.initials: M
authors.lastname: Larrousse
authors.forename: Javier
authors.initials: J
authors.lastname: Murillas
authors.forename: José Luis
authors.initials: JL
authors.lastname: Blanco
authors.forename: Agathe
authors.initials: A
authors.lastname: León
authors.forename: Ana
authors.initials: A
authors.lastname: Milinkovic
authors.forename: Montserrat
authors.initials: M
authors.lastname: Loncá
authors.forename: Esteban
authors.initials: E
authors.lastname: Martinez
authors.forename: José Maria
authors.initials: JM
authors.lastname: Sánchez-Tapias
authors.forename: Elisa
authors.initials: E
authors.lastname: de Lazzari
authors.forename: Josep Maria
authors.initials: JM
authors.lastname: Gatell
authors.forename: Josep
authors.initials: J
authors.lastname: Costa
authors.forename: Josep
authors.initials: J
authors.lastname: Mallolas
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy*; D016174:Hepacivirus / Q000302:isolation & purification; D006526:Hepatitis C / Q000150:complications* / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D011092:Polyethylene Glycols; D011237:Predictive Value of Tests; D012367:RNA, Viral / Q000097:blood; D011994:Recombinant Proteins; D012254:Ribavirin / Q000008:administration & dosage / Q000627:therapeutic use*; D019562:Viral Load
chemical_list: D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D012367:RNA, Viral; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C417083:peginterferon alfa-2b